10-Q: NeuroOne Reports Q1 Loss, Nasdaq Delisting Risk Looms

NeuroOne Medical Technologies Corporation reported a net loss of $1.44 million in Q1 2026, a significant decline from the prior year's profit, alongside ongoing Nasdaq compliance issues and substantial doubt about its ability to continue as a going concern.

Summary

• A net loss of $1.44 million was reported for the three months ended December 31, 2025, a significant decline from the net income of $1.79 million in the comparable prior year period.
• Product revenue decreased to $2.89 million for the quarter, down from $3.27 million in the prior year, with product gross profit percentage falling to 54.2% from 58.9%.
• No license revenue was recognized in the current quarter, compared to $3.0 million in the prior year, which was a one-time payment from the Zimmer distribution agreement.
• Cash and cash equivalents significantly decreased by $3.01 million during the quarter, ending at $3.56 million as of December 31, 2025, down from $6.57 million at September 30, 2025.
• Net cash used in operating activities increased substantially to $3.12 million for the quarter, compared to net cash provided of $0.21 million in the prior year, indicating a higher cash burn.
• The accumulated deficit grew to $80.0 million as of December 31, 2025.
• The company initiated a limited market release of its OneRF TN Ablation System in December 2025.
• Nasdaq granted a 180-day extension until May 4, 2026, for the company to regain compliance with the minimum bid price requirement.
• A material weakness in internal controls over financial reporting, specifically due to insufficient segregation of duties, was identified, with remediation plans currently being implemented.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a concerning report given the significant shift to a net loss, increased cash burn from operations, declining product revenue, and the explicit "going concern" warning. The Nasdaq delisting risk further adds to the negative sentiment, despite some product development progress.

Positives

• Initiated a limited market release of the OneRF TN Ablation System in December 2025, expanding product commercialization efforts.
• Successfully obtained 510(k) clearance from the FDA for four devices, including Evo cortical, Evo sEEG, OneRF Ablation System, and OneRF TN Ablation System.
• Secured an exclusive distribution agreement with Zimmer, Inc. for key products (Evo Cortical, Evo sEEG, and OneRF Ablation System).
• Selling, general and administrative expenses decreased by approximately $0.1 million, primarily due to lower legal, investor relations, and other professional service fees.
• The fair value change in warrant liability resulted in a benefit of $0.2 million for the quarter.

Negatives

• Shifted from a net income of $1.79 million in Q1 2025 to a net loss of $1.44 million in Q1 2026.
• Product revenue decreased by $381,532 to $2.89 million in Q1 2026 compared to $3.27 million in Q1 2025.
• Product gross profit percentage declined to 54.2% from 58.9% year-over-year, attributed to higher direct customer sales at discount pricing in the current period, increased material costs, and lower sales volume.
• No license revenue was recognized in Q1 2026, a significant drop from $3.0 million in Q1 2025, which was a one-time payment from the Zimmer distribution agreement.
• Cash and cash equivalents significantly decreased by $3.01 million during the quarter, from $6.57 million to $3.56 million.
• Net cash used in operating activities was $3.12 million, a substantial increase from net cash provided of $0.21 million in the prior year, indicating increased cash burn.
• Accumulated deficit increased to $80.0 million as of December 31, 2025.
• Research and development expenses increased by $0.2 million to $1.39 million, driven by consulting services, materials, and supplies for new drug delivery technology applications.
• The company received a Nasdaq notification for non-compliance with the minimum bid price requirement and was granted an extension until May 4, 2026, to regain compliance, indicating potential delisting risk.
• Identified a material weakness in internal controls over financial reporting due to insufficient segregation of duties.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to incurred losses since inception, negative cash flows from operations, and an accumulated deficit of $80.0 million.
• Inability to raise additional funds on favorable terms or at all would materially adversely affect operations and technology development, or could lead to cessation of operations.
• Dependence on a single customer for 100% of product revenue in the current quarter poses significant concentration risk.
• Reliance on a single contract manufacturer for Strip/Grid and sEEG Products and another supplier for the OneRF Ablation system generator creates supply chain vulnerability.
• Uncertainty in worldwide economic conditions, including conflicts (Russia/Ukraine, Middle East), banking system disruptions, inflation, and increased interest rates, could adversely affect access to capital and increase costs.
• Potential for further price increases from suppliers related to tariffs on imported goods and overall macroeconomic factors.
• Risk of delisting from The Nasdaq Capital Market if the company fails to regain compliance with the minimum bid price requirement by May 4, 2026.
• A material weakness in internal controls over financial reporting due to insufficient segregation of duties increases the risk of undetected errors or misstatements.
• The development and commercialization of medical devices are costly, and the timing of progress in pre-clinical tests and clinical trials is uncertain, potentially leading to faster-than-expected cash burn.
• Zimmer's failure to timely develop or commercialize products under the distribution agreement would have a material adverse effect on the business and operating results.
• Potential for various claims and legal proceedings in the ordinary course of business, which could incur defense and settlement costs and divert management resources.

Future Outlook

The company expects to continue incurring significant expenses and increasing operating and net losses for the foreseeable future until it generates a higher level of revenue from commercial sales. It anticipates that current cash and cash equivalents, combined with expected increases in product revenues from Zimmer and operating expense reductions, will fund operations through September 2026. However, the ability to raise additional funds on favorable terms or at all is uncertain, and failure to do so could materially adversely affect operations or lead to cessation of operations. The development and commercialization of medical devices are costly, with uncertain timing for pre-clinical and clinical trials.

Management Comments

• "We expect to continue to incur significant expenses and may incur increasing operating and net losses for the foreseeable future until we generate a higher level of revenue from commercial sales."
• "We may be unable to raise additional funds when needed on favorable terms or at all."
• "Management has noted the existence of substantial doubt about our ability to continue as a going concern."
• "If we are unable to raise additional funds, or if our anticipated operating results are not achieved, we believe planned expenditures may need to be reduced in order to extend the time period that existing resources can fund our operations."

Industry Context

StockSavvy.ai notes that NeuroOne operates in the highly competitive and capital-intensive medical technology sector, specifically neuromodulation. The company's reliance on a single distribution partner (Zimmer) and a concentrated customer base for product revenue highlights a significant business risk, contrasting with broader industry trends towards diversified revenue streams and robust supply chains. The ongoing global economic uncertainties, including inflation and supply chain constraints, are common challenges across the medtech industry, but NeuroOne's "going concern" warning indicates a more acute vulnerability compared to more established players. The initiation of a limited market release for the OneRF TN Ablation System is a positive step in product commercialization, but its impact on profitability remains to be seen in a market dominated by larger, well-funded competitors.

Corporate Governance

Legal Proceedings

• Not currently a party to any legal proceedings that, in management's opinion, are likely to have a material adverse effect on the business.
• Acknowledges that litigation can have an adverse impact due to defense and settlement costs, diversion of management resources, and other factors.

Related Party Transactions

• Paul Buckman, a director on the Company's Board of Directors, was one of the purchasers in the August 2024 Private Placement.
• The exercise price of PIPE Warrants for 20,834 shares issued to a director (Paul Buckman) was reset to $0.876 per share, while other PIPE Warrants were reset to $0.465.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future equity financings, risk of delisting from Nasdaq, and potential loss of investment due to "going concern" doubt.
• Employees have stock-based compensation plans in place, but the company did not make 401(k) matching contributions in the current quarter. Job security could be impacted by the "going concern" risk.
• Customers' continued product availability and development are tied to the company's financial stability and ability to fund operations.
• Suppliers may experience minor price increases due to tariffs and macroeconomic conditions. Payment terms could be affected by the company's liquidity challenges.
• Creditors face increased risk due to the "going concern" warning and the company's reliance on future capital raises.

Next Steps

• Regain compliance with Nasdaq's minimum bid price requirement by May 4, 2026.
• Continue implementing measures to remediate the material weakness in internal controls over financial reporting.
• Generate higher levels of revenue from commercial sales to cover operating costs and achieve profitability.
• Raise additional capital through equity or debt financing to fund ongoing operations beyond September 2026.
• Continue product development and commercialization activities, including pre-clinical and clinical trials.
• Zimmer to meet Minimum Purchase Requirements for RF Products for Q4 2025 and each quarter of 2026.
• Parties to mutually agree on Minimum Purchase Requirements for SEEG-RF Electrode and Temperature Accessory Kit for 2027 et seq. by the specified date each calendar year.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a significant net loss, increased cash burn from operations, and an explicit "going concern" warning from management and auditors. Product revenue is declining, and there's a critical Nasdaq delisting risk due to the low share price. While there are product clearances and a distribution agreement, the fundamental financial health and ability to fund operations are in serious doubt, making the stock a high-risk, speculative investment with significant downside potential. The material weakness in internal controls further compounds the risk profile.

Keywords

NeuroOne Medical Technologies, NMTC, 10-Q, Quarterly Report, Medical Technology, Neuromodulation, Epilepsy, Trigeminal Neuralgia, Parkinson's Disease, Dystonia, Essential Tremors, Chronic Pain, Surgical Devices, FDA 510(k) Clearance, Evo Cortical, Evo sEEG, OneRF Ablation System, OneRF TN Ablation System, Zimmer Distribution Agreement, Going Concern, Nasdaq Compliance, Minimum Bid Price, Financial Performance, Net Loss, Cash Flow, Research and Development, Internal Controls, Capital Raise, Warrants, Stock-based Compensation